US private equity firm buys 30% of India's Nectar
This article was originally published in Scrip
The US private equity firm, New Silk Route Partners (NSR), has invested Rs2.52 billion ($54.9 million) in Nectar Lifesciences of India.
You may also be interested in...
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.
Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.